ANYA BIOPHARM INC.

ANYA BIOPHARM INC. was founded in 2016 to address the challenges of low bioavailability, poor efficacy, and limited drug development options for orally administered peptide drugs. Their core platform, MIRA/JE®, incorporates 30 combinations of MIRA (Metal Ion and Reducing Agent) and PE (Permeation Enhancer) to optimize formulations for different peptides. Unlike other platforms focusing on a single factor, ANYA's platform regulates multiple aspects simultaneously. The manufacturing process is straightforward and scalable, using Generally Recognized as Safe (GRAS) raw materials, and solid dosage forms can be produced in multiple GMP facilities. Their product development strategy emphasizes platform validation before commercialization.